 "Pfizer dips after ban on Corex cough syrup in India")
Shares of Pfizer have dipped 5% to Rs 1,827 on the BSE, after the company announced that it has discontinued the manufacturing and sale of its popular drug “Corex”.
“The Government of India has prohibited the manufacture for sale, sale and distribution of fixed dose combination of Chlopheniramine Maleate + Codeine Syrup with immediate effect,” Pfizer said in a statement.
The prohibition on Corex is likely to have an adverse impact on revenue and profitability of the company. Corex recorded a sale of Rs 176 crore for the nine months period ended December 2015, the company said.
Corex has a well-established efficacy and safety profile in India for more than 30 years and Pfizer makes every effort to maintain the highest standards of regulatory and quality compliance in the manufacturing and distribution of Corex Cough Syrup. The company is exploring all possible options at its disposal, it added.
Till 10:44 AM, a combined 44,635 shares changed hands on the counter on the BSE and NSE so far.
“The Government of India has prohibited the manufacture for sale, sale and distribution of fixed dose combination of Chlopheniramine Maleate + Codeine Syrup with immediate effect,” Pfizer said in a statement.
Read more from our special coverage on "PFIZER"
The prohibition on Corex is likely to have an adverse impact on revenue and profitability of the company. Corex recorded a sale of Rs 176 crore for the nine months period ended December 2015, the company said.
Corex has a well-established efficacy and safety profile in India for more than 30 years and Pfizer makes every effort to maintain the highest standards of regulatory and quality compliance in the manufacturing and distribution of Corex Cough Syrup. The company is exploring all possible options at its disposal, it added.
Till 10:44 AM, a combined 44,635 shares changed hands on the counter on the BSE and NSE so far.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%